Reviewer’s report

Title: The presence of KIR2DS4 full-length gene decreases a chance of rheumatoid arthritis patients to respond to methotrexate treatment

Version: 2
Date: 23 February 2014
Reviewer: Jeng-Hsien Yen

Reviewer’s report:

This is a manuscript concerning the influence of KIR genotypes on the response of RA therapy. Several comments as follows.

1. In addition to MTX, is there any other DMARD combined in this study?
2. The definitions for good and poor responses may be inadequate. It is not easy to achieve complete remission in the treatment of RA. Therefore, it is not adequate to use whether remission or not as the response criteria. Furthermore, the definition for remission of RA is not DAS28 < 2.4. It is suggested to use EULAR response criteria in this study.

Level of interest: An article of limited interest

Quality of written English: Not suitable for publication unless extensively edited

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests.